Effect of acetylsalicyclic acid and dipyridamole in primary membranoproliferative glomerulonephritis type I

被引：7

作者：

Harmankaya Ö. ^{[1
]}

Baştürk T. ^{[1
]}

Öztürk Y. ^{[1
]}

Karabiber N. ^{[1
]}

Öbek A. ^{[1
]}

机构：

[1] Department of Nephrology, Şişli Etfal Training and Research Hospital, Istanbul

来源：

International Urology and Nephrology | 2001年 / 33卷 / 3期

关键词：

Acetylsalicylic acid; Dipyridamole; Membranoproliferative glomerulonephritis; Proteinuria;

D O I：

10.1023/A:1019546617485

中图分类号：

学科分类号：

摘要：

Primary membranoproliferative glomerulonephritis (MPGN) has a poor long-term prognosis, with 40 per cent of patients reaching end-stage renal failure after 10 years of observation. Approximately 35 per cent of patients die due to complications of the nephrotic syndrome. This study investigates the effect of acetylsalicylic acid (ASA) combined with dipyridamole on proteinuria and renal function in nephrotic MPGN patients with normal/moderately reduced glomerular filtration rate (GFR). Fourteen patients with biopsy-proven type I MPGN received ASA (1000 mg/day) and dipyridamole (300 mg/day) for 24 months. Proteinuria was reduced from 6.8 ± 2.4 g/day to 1.1 ± 0.6 g/day (p < 0.001). Serum albumin levels increased from 2.2 ± 0.5 g/dL to 3.7 ± 0.4 g/dL (p < 0.001) during the study period after 24 months compared to baseline. Serum creatinine and GFR did not significantly change in patients treated with acetylsaliclylic acid and dipyridamole during the observation period (p < 0.05). Our study suggests that ASA combined with dipyridamole significantly reduces proteinuria without impairing renal function in patients with MPGN.

引用

页码：583 / 587

页数：4

共 18 条

[1]

Williams D.G., Mesangiocapillary glomerulonephritis, Oxford Textbook of Clinical Nephrology, 2nd Edition, 1, pp. 591-612, (1998)

[2]

Glassock R., Membranoproliferative glomerulonephritis, Treatment of Primary Glomerulonephritis, pp. 218-233, (1998)

[3]

Glassock R., Cohen A., Adler S., Primary glomerular disease, The Kidney, 5th Edition, 2, pp. 1458-1466, (1995)

[4]

Donadio J.V., Offord K., Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis, Am J Kidney Dis, 6, pp. 445-451, (1989)

[5]

Erbay B., Karatan O., Duman N., The effects of cyclosporine in idiopathic nephrotic syndrome resistant to immunosuppressive therapy, Transplant, (1988)

[6]

Tiller D., Clarkson A., Matthew T., A prospective randomized trial of the use of cyclophosphamide, dipyridamole and warfarin in membranous and membranoproliferative glomerulonephritis, Proceedings of the 8th International Congress on Nephrology, pp. 345-351, (1981)

[7]

Cattran D.C., Cardella C., Roscoe J., Results of a controlled drug trial in membranoproliferative glomerulonephritis, Kidney Int, 27, pp. 436-441, (1985)

[8]

Donadio J.V., Anderson C., Mitchell J., Et al., Membranoproliferative glomerulonephritis, a clinical trial of platelet inhibitor therapy, N Engl J Med, 310, 22, pp. 1421-1426, (1984)

[9]

Knotkova V., Petru I., Nemecek K., Et al., Treatment of chronic proliferative glomerulonephritis using acetylsalicylic acid and dipyridamole, Cas Lek Cesk, 128, 26, pp. 814-818, (1989)

[10]

Zauner I., Bohler J., Braun N., Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: A multi-centre prospective clinical trial, Nephrol Dial Transplant, 9, 6, pp. 619-622, (1994)

← 1 2 →